SEC Company Response from Summit Therapeutics Inc. (SMMT) (CIK 0001599298) (SMMT) — Jun 18, 2019
Summit Therapeutics Inc. (SMMT) (CIK 0001599298)
Date: June 18, 2019 · CIK: 0001599298 · Accession: 0001193125-19-175621
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-232074
Letter
Summit Therapeutics plc
136a Eastern Avenue
Milton Park, Abingdon
Oxfordshire OX14 4SB
United Kingdom
June 18, 2019
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Summit Therapeutics plc
Registration Statement on Form F-3
File No. 333-232074
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Summit Therapeutics plc (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form F-3 (File No. 333-232074) (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern Time on June 20, 2019, or as soon thereafter as practicable.
Very truly yours,
SUMMIT THERAPEUTICS PLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP Summit Therapeutics plc 136a Eastern Avenue Milton Park, Abingdon Oxfordshire OX14 4SB United Kingdom June 18, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Summit Therapeutics plc Registration Statement on Form F-3 File No. 333-232074 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Summit Therapeutics plc (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form F-3 (File No. 333-232074) (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern Time on June 20, 2019, or as soon thereafter as practicable. Very truly yours, SUMMIT THERAPEUTICS PLC By: /s/ Glyn Edwards Name: Glyn Edwards Title: Chief Executive Officer